The stock's fall snapped a four-day winning streak.

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

This was the stock's fourth consecutive day of gains.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.